A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care

Pediatric Pulmonology

Volumn 48, Issue 10, 2013, Pages 954-961

  Sawicki, Gregory S ^a   Ayyagari, Rajeev ^b   Zhang, Jie ^c   Signorovitch, James E ^b   Fan, Liangyi ^b   Swallow, Elyse ^b   Latremouille Viau, Dominick ^b   Wu, Eric Q ^b   Shi, Lizheng ^d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b ANALYSIS GROUP   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d TULANE UNIVERSITY   (United States)

Author keywords

anti bacterial agents; medication therapy management; Pseudomonas aeruginosa; registries; risk assessment

Indexed keywords

BRONCHODILATING AGENT; DORNASE ALFA; TOBRAMYCIN;

ADULT; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; BURKHOLDERIA CEPACIA; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT CARE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULMONARY EXACERBATION RISK SCORE; REGISTER; VALIDATION PROCESS;

ANTI-BACTERIAL AGENTS; MEDICATION THERAPY MANAGEMENT; PSEUDOMONAS AERUGINOSA; REGISTRIES; RISK ASSESSMENT;

ADULT; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; FEMALE; HUMANS; LOGISTIC MODELS; LUNG; MALE; RECOMBINANT PROTEINS; RISK FACTORS; TOBRAMYCIN; YOUNG ADULT;

EID: 84884135322     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22741     Document Type: Article

References (32)

1. Cystic Fibrosis Foundation Patient Registry. 2009 Annual Data Report. Bethesda, Maryland. © 2011 Cystic Fibrosis Foundation.
2. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B,. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001; 139: 359-365.
3. Goss CH, Burns JL,. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007; 62: 360-367.
4. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME,. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642.
5. Flume PA, Mogayzel PJ, Jr., Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC,. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180: 802-808.
6. Kraynack NC, Gothard MD, Falletta LM, McBride JT,. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol 2011; 46: 870-881.
7. Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, Johnson CA, Konstan MW, Regelmann WE,. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004; 37: 400-406.
8. Vandevanter DR, Yegin A, Morgan WJ, Millar SJ, Pasta DJ, Konstan MW,. Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint. J Cyst Fibros 2011; 10: 453-459.
9. Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F,. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012; 40: 61-66.
10. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW,. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002; 121: 64-72.
11. Lieu TA, Ray GT, Farmer G, Shay GF,. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999; 103: e72.
12. Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH,. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010; 45: 127-134.
13. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH,. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182: 627-632.
14. Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH,. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011; 46: 393-400.
15. de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, Paterson N, Jackson M, Lougheed MD, Kumar V, Aaron SD,. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011; 66: 680-685.
16. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC,. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153: 345-352.
17. Ellaffi M, Vinsonneau C, Coste J, Hubert D, Burgel PR, Dhainaut JF, Dusser D,. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med 2005; 171: 158-164.
18. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Jr., Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B, Cystic Fibrosis Foundation PTC. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-969.
19. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL,. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30.
20. Garber E, Desai M, Zhou J, Alba L, Angst D, Cabana M, Saiman L,. Barriers to adherence to cystic fibrosis infection control guidelines. Pediatr Pulmonol 2008; 43: 900-907.
21. Modi AC, Quittner AL,. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way ? J Pediatr Psychol 2006; 31: 846-858.
22. Bucks RS, Hawkins K, Skinner TC, Horn S, Seddon P, Horne R,. Adherence to treatment in adolescents with cystic fibrosis: the role of illness perceptions and treatment beliefs. J Pediatr Psychol 2009; 34: 893-902.
23. Quittner AL, Drotar D, Ievers-Landis C, Seidner D, Slocum N, Jacobsen J,. Adherence to medical treatments in adolescents with cystic fibrosis: the development and evaluation of family-based interventions. In:, Drotar D, editor. Promoting adherence to medical treatment in childhood chronic illness: concepts, methods, and interventions. Mahwah N.J.: Lawrence Erlbaum Associate; 2000. pp 383-407.
24. Rosenbluth DB, Wilson K, Ferkol T, Schuster DP,. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest 2004; 126: 412-419.
25. Forno E, Fuhlbrigge A, Soto-Quiros ME, Avila L, Raby BA, Brehm J, Sylvia JM, Weiss ST, Celedon JC,. Risk factors and predictive clinical scores for asthma exacerbations in childhood. Chest 2010; 138: 1156-1165.
26. Block JK, Vandemheen KL, Tullis E, Fergusson D, Doucette S, Haase D, Berthiaume Y, Brown N, Wilcox P, Bye P, Bell S, Noseworthy M, Pedder L, Freitag A, Paterson N, Aaron SD,. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax 2006; 61: 969-974.
27. Tibshirani R,. Regression shrinkage and selection via the Lasso. J Roy Stat Soc Ser B (Methodological) 1996; 58: 267-288.
28. VanDevanter DR, Wagener JS, Pasta DJ, Elkin E, Jacobs JR, Morgan WJ, Konstan MW,. Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatr Pulmonol 2010; 45: 1156-1166.
29. Ohman EM, Granger CB, Harrington RA, Lee KL,. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA 2000; 284: 876-878.
30. Weatherly MR, Palmer CG, Peters ME, Green CG, Fryback D, Langhough R, Farrell PM,. Wisconsin cystic fibrosis chest radiograph scoring system. Pediatrics 1993; 91: 488-495.
31. Conway SP, Pond MN, Bowler I, Smith DL, Simmonds EJ, Joanes DN, Hambleton G, Hiller EJ, Stableforth DE, Weller P, et al. The chest radiograph in cystic fibrosis: a new scoring system compared with the Chrispin-Norman and Brasfield scores. Thorax 1994; 49: 860-862.
32. Cleveland RH, Neish AS, Zurakowski D, Nichols DP, Wohl ME, Colin AA,. Cystic fibrosis: a system for assessing and predicting progression. AJR Am J Roentgenol 1998; 170: 1067-1072.